Verimatrix Wins 2023 NAB Show Product of the Year Award
Regulatory News:
Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Verimatrix Streamkeeper was selected as a recipient of a 2023 NAB Show Product of the Year Award for the use of artificial intelligence (AI) and machine learning (ML).
Recognizing some of the most significant and promising new products and technologies showcased by exhibitors at this year’s NAB Show, the event’s official award program selects winners via a panel of industry experts in 15 categories. Recipients were announced April 18 at an awards ceremony during the 2023 NAB Show in Las Vegas. To be eligible for an award, nominated products had to come from companies exhibiting at the 2023 NAB Show and be delivered within the 2023 calendar year.
Verimatrix Streamkeeper stands as the industry’s first battle-ready cybersecurity solution specifically engineered to hunt down and take out video piracy – resulting in consistent video content loss prevention and protected profits. Setting a new benchmark for video security, Streamkeeper protects the full streaming (OTT) distribution ecosystem and combines Multi-DRM, Watermarking, App Shield and Counterspy™ — the company’s zero-code, anti-piracy deployment technology.
“During our centennial year, NAB continues to recognize the products that are transforming how content is being created, connected and capitalized throughout the broadcast, media and entertainment industry,” said NAB SVP and Chief Customer Success Officer Eric Trabb. “Congratulations to Verimatrix for winning the 2023 NAB Show Product of the Year Award in recognition of Streamkeeper, a product that has demonstrated its ability to help storytellers face the challenges of the present and future by revolutionizing a critical stage of the content lifecycle.”
“It’s truly an honor to have Verimatrix Streamkeeper named Product of the Year for AI/ML at this year’s NAB Show,” said Asaf Ashkenazi, CEO of Verimatrix. “Our collaborative machine/human approach to combatting video piracy is one-of-a-kind; attack patterns can be detected quickly and accurately with artificial intelligence, but our human data scientists compliment machines by ensuing clarity of investigation, precision of response, and safety in oversight. The result is a collaborative, human-centered AI/ML security solution that helps combat the riskiest threat instances with surgical precision: cutting off criminals without denigrating the user experience for legitimate customers.”
To learn more about Streamkeeper and how it prevents industrial-scale video piracy, visit www.verimatrix.com/products/streamkeeper.
About NAB Show
NAB Show, held April 15-19, 2023, in Las Vegas, is celebrating its centennial year as the preeminent conference and exhibition driving the evolution of broadcast, media, and entertainment. It is the ultimate marketplace for next generation technology inspiring superior audio and video experiences. From creation to consumption, across multiple platforms, NAB Show is where global visionaries convene to bring content to life in new and exciting ways. More information is available at www.nabshow.com. About NAB The National Association of Broadcasters is the premier advocacy association for America's broadcasters. NAB advances radio and television interests in legislative, regulatory, and public affairs. Through advocacy, education, and innovation, NAB enables broadcasters to best serve their communities, strengthen their businesses and seize new opportunities in the digital age. Visit www.nab.org.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005416/en/
Contact information
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
Verimatrix Media Contacts:
USA
Matthew Zintel, Zintel Public Relations
matthew.zintel@zintelpr.com
Europe
Lara Joseph, Eskenzi PR
lara@eskenzipr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom